pioglitazone has been researched along with Nerve Pain in 12 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| " 2) Systemic administration of a PPARγ agonist, pioglitazone (PIO), attenuates whisker pad mechanical allodynia at doses of 300 mg/kg i." | 3.85 | PPARγ Agonists Attenuate Trigeminal Neuropathic Pain. ( Danaher, RJ; Lyons, DN; Miller, CS; Westlund, KN; Zhang, L, 2017) |
| " However, there is no published report on the effect of pioglitazone as an antidepressant in the treatment of depression induced by neuropathic pain with CCI in rats." | 3.85 | Possible modulation of PPAR-γ cascade against depression caused by neuropathic pain in rats. ( Deshmukh, VR; Garg, S; Prasoon, P, 2017) |
| "First, employing neuropathic pain models with chronic duration is critical since they can encompass the continuum of molecular and brain circuitry alterations arising over time when pain persists, providing greater relevance to clinical pain syndromes." | 2.66 | Building and Testing PPARγ Therapeutic ELB00824 with an Improved Therapeutic Window for Neuropathic Pain. ( Westlund, KN; Zhang, M, 2020) |
| "Cisplatin produced mechanical and cold hyperalgesia and decreased electrical thresholds of Aδ and C fibers, which were attenuated by coadministration of pioglitazone (10 mg/kg, intraperitoneally [i." | 1.51 | Pioglitazone, a PPARγ agonist, reduces cisplatin-evoked neuropathic pain by protecting against oxidative stress. ( Albino-Ramírez, AM; Khasabov, SG; Khasabova, IA; Kim, AH; Olson, JK; Seybold, VS; Simone, DA; Uhelski, ML; Wagner, CL, 2019) |
| "Treatment with pioglitazone and ceftriaxone significantly prevented these behavioral, biochemical, mitochondrial and cellular alterations in rats." | 1.43 | Ameliorative potential of pioglitazone and ceftriaxone alone and in combination in rat model of neuropathic pain: Targeting PPARγ and GLT-1 pathways. ( Bhatnagar, A; Ekavali, E; Garg, S; Kumar, A; Pottabathini, R, 2016) |
| "Pioglitazone inhibited hyperalgesia within 5 minutes of injection, consistent with a nongenomic mechanism." | 1.42 | Pioglitazone rapidly reduces neuropathic pain through astrocyte and nongenomic PPARγ mechanisms. ( Donahue, RR; Grace, PM; Griggs, RB; Morgenweck, J; Sutton, A; Taylor, BK; Watkins, LR, 2015) |
| "Pioglitazone or vehicle was administered 1h before operation and continued daily to day 14 after operation." | 1.39 | Spinal neuroimmune activation inhibited by repeated administration of pioglitazone in rats after L5 spinal nerve transection. ( Ji, Q; Jia, HB; Liu, XY; Qiu, LL; Shen, JC; Wang, XM; Yang, JJ, 2013) |
| "Mechanical hyperalgesia was measured using Von-Frey filament tests before and after the surgery." | 1.36 | Repeated administration of pioglitazone attenuates development of hyperalgesia in a rat model of neuropathic pain. ( Duan, M; Hui, K; Ji, Q; Jia, H; Li, W; Xu, J; Zhu, S, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (75.00) | 24.3611 |
| 2020's | 3 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Santos, DFS | 1 |
| Donahue, RR | 3 |
| Laird, DE | 1 |
| Oliveira, MCG | 1 |
| Taylor, BK | 3 |
| Bian, J | 1 |
| Zhang, B | 1 |
| Zhang, Y | 1 |
| Tian, Y | 1 |
| Yin, L | 1 |
| Zou, W | 1 |
| Westlund, KN | 3 |
| Zhang, M | 1 |
| Lyons, DN | 2 |
| Zhang, L | 2 |
| Danaher, RJ | 2 |
| Miller, CS | 2 |
| Pandya, JD | 1 |
| Ma, F | 1 |
| Sullivan, PG | 1 |
| Sirbu, C | 1 |
| Garg, S | 2 |
| Deshmukh, VR | 1 |
| Prasoon, P | 1 |
| Khasabova, IA | 1 |
| Khasabov, SG | 1 |
| Olson, JK | 1 |
| Uhelski, ML | 1 |
| Kim, AH | 1 |
| Albino-Ramírez, AM | 1 |
| Wagner, CL | 1 |
| Seybold, VS | 1 |
| Simone, DA | 1 |
| Morgenweck, J | 2 |
| Griggs, RB | 2 |
| Zadina, JE | 1 |
| Jia, HB | 1 |
| Wang, XM | 1 |
| Qiu, LL | 1 |
| Liu, XY | 1 |
| Shen, JC | 1 |
| Ji, Q | 2 |
| Yang, JJ | 1 |
| Grace, PM | 1 |
| Sutton, A | 1 |
| Watkins, LR | 1 |
| Pottabathini, R | 1 |
| Kumar, A | 1 |
| Bhatnagar, A | 1 |
| Ekavali, E | 1 |
| Jia, H | 1 |
| Zhu, S | 1 |
| Hui, K | 1 |
| Duan, M | 1 |
| Xu, J | 1 |
| Li, W | 1 |
1 review available for pioglitazone and Nerve Pain
| Article | Year |
|---|---|
Building and Testing PPARγ Therapeutic ELB00824 with an Improved Therapeutic Window for Neuropathic Pain.
Topics: Animals; Humans; Hyperalgesia; Mice; Neuralgia; Pioglitazone; PPAR gamma; Rats; Rosiglitazone; Thiaz | 2020 |
11 other studies available for pioglitazone and Nerve Pain
| Article | Year |
|---|---|
The PPARγ agonist pioglitazone produces a female-predominant inhibition of hyperalgesia associated with surgical incision, peripheral nerve injury, and painful diabetic neuropathy.
Topics: Analgesics; Animals; Diabetic Neuropathies; Disease Models, Animal; Female; Hyperalgesia; Male; Mice | 2022 |
FGF 10 Inhibited Spinal Microglial Activation in Neuropathic Pain via PPAR-γ/NF-κB Signaling.
Topics: Analgesics; Animals; Fibroblast Growth Factor 10; Hyperalgesia; Lipopolysaccharides; Neuralgia; NF-k | 2022 |
PPARγ Agonists Attenuate Trigeminal Neuropathic Pain.
Topics: Analgesics, Non-Narcotic; Anilides; Animals; Disease Models, Animal; Facial Pain; Hyperalgesia; Male | 2017 |
Combination Drug Therapy of Pioglitazone and D-cycloserine Attenuates Chronic Orofacial Neuropathic Pain and Anxiety by Improving Mitochondrial Function Following Trigeminal Nerve Injury.
Topics: Analgesics; Animals; Anti-Anxiety Agents; Anxiety; Brain; Chronic Pain; Cognition; Cycloserine; Dise | 2018 |
Possible modulation of PPAR-γ cascade against depression caused by neuropathic pain in rats.
Topics: Animals; Brain; Catalase; Depression; Dose-Response Relationship, Drug; Glutathione; Immobility Resp | 2017 |
Pioglitazone, a PPARγ agonist, reduces cisplatin-evoked neuropathic pain by protecting against oxidative stress.
Topics: Animals; Antineoplastic Agents; Cells, Cultured; Cisplatin; Disease Models, Animal; Female; Ganglia, | 2019 |
PPARγ activation blocks development and reduces established neuropathic pain in rats.
Topics: Anilides; Animals; Ataxia; CD11b Antigen; Dose-Response Relationship, Drug; Drug Administration Sche | 2013 |
Spinal neuroimmune activation inhibited by repeated administration of pioglitazone in rats after L5 spinal nerve transection.
Topics: Animals; Cytokines; Glial Fibrillary Acidic Protein; Hyperalgesia; Male; Neuralgia; Neuroimmunomodul | 2013 |
Pioglitazone rapidly reduces neuropathic pain through astrocyte and nongenomic PPARγ mechanisms.
Topics: Analysis of Variance; Animal Diseases; Animals; Area Under Curve; Astrocytes; Capsaicin; Glial Fibri | 2015 |
Ameliorative potential of pioglitazone and ceftriaxone alone and in combination in rat model of neuropathic pain: Targeting PPARγ and GLT-1 pathways.
Topics: Animals; Ceftriaxone; Disease Models, Animal; Drug Delivery Systems; Drug Therapy, Combination; Exci | 2016 |
Repeated administration of pioglitazone attenuates development of hyperalgesia in a rat model of neuropathic pain.
Topics: Animals; Brain; Cytokines; Disease Models, Animal; Hyperalgesia; Interleukin-1beta; Male; Neuralgia; | 2010 |